Research programme: antibody-based tumour diagnostics - Enlyton
Latest Information Update: 16 Jul 2016
At a glance
- Originator Enlyton
- Developer Applied Biomolecular Technologies; Enlyton; Ohio State University; Quanta BioDesign
- Class Antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Single-photon emission-computed tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Adenocarcinoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Adenocarcinoma(Diagnosis) in USA (Parenteral)
- 18 Sep 2012 Preclinical trials in Adenocarcinoma (diagnostic) in USA (Parenteral)